ABSTRACT -Background -Infection by hepatitis C virus is one of the leading causes of chronic hepatitis C and cause severe burden for patients, families and the health care system. Objective -The aims of this research were to assess the severity of liver fibrosis, comorbidities and complications of hepatitis C virus; to examine health-related quality of life (HRQoL), productivity loss and resource use and costs in a sample of Brazilian chronic hepatitis C, genotype 1, patients. Methods -This was a cross-sectional multicenter study performed in genotype-1 chronic hepatitis C patients to assess disease burden in the Brazilian public health care system between November 2014 and March 2015. Patients were submitted to a liver transient elastography (FibroScan) to assess liver fibrosis and answered an interview composed by a questionnaire specifically developed for the study and three standardized questionnaires: EQ-5D-3L, HCV-PRO and WPAI:HepC. Results -There were 313 subjects enrolled, with predominance of women (50.8%), caucasian/ white (55.9%) and employed individuals (39.9%). Mean age was 56 (SD=10.4) years old. Moreover, 42.8% of patients who underwent FibroScan were cirrhotic; the most frequent comorbidity was cardiovascular disease (62.6%) and the most frequent complication was esophageal varices (54.5%).
INTRODUCTION
Infection by hepatitis C virus (HCV) is one of the leading causes of chronic liver disease; however, the majority of the infected individuals is not diagnosed. It is estimated that there are approximately 170-200 million people infected globally and 2.5 million people in Brazil (1) (2) (3) (4) . The prevalence of HCV genotypes vary across countries (5) . Given Brazil's continental size, it is expected that this prevalence also varies among regions. A comprehensive study enrolling 1,688 sequential samples from chronic HCV patients found a statistical significant difference regarding patterns of genotypes distribution among regions (P=0.00017). However, genotype 1 was the most frequent in all regions, ranging from 51.7% in the South to 74.1% in the North (6) . HCV symptoms may include malaise, weakness, anorexia, and jaundice, although the illness rarely causes acute symptomatic infection (7) . There is a lot of evidence showing that hepatitis C can lead Hepatitis C in the Brazilian public health care system: burden of disease to persistent infection in a high proportion of infected individuals, and it can progress to chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) (8) . Chronic hepatitis C (CHC) causes severe burden for patients, families, and the health care system, once the economic implications include not only costs related to disease management, but also consequences of productivity loss (4) (5) (6) (7) (8) (9) . It is estimated that CHC is responsible for approximately 350,000 deaths per year in United States (10) . In Brazil, Ministry of Health provides access to HCV treatment since 2002, following a National Guideline applied only to the Brazilian public healthcare system that includes interferon or pegylated interferon, ribavirin, sofosbuvir, simeprevir, daclatasvir and ombitasvir/veruprevir/ritonavir plus dasabuvir (11) (12) (13) (14) . Patients receiving those therapies through government funding need to be attending a public medical facility specialized in HCV treatment. Other therapies not currently available in this National Guidelines can be obtained in the private setting through health insurance coverage or as a patient out-of-pocket expense (13) .
AG-2018-43
dx.doi.org/10.1590/S0004-2803.201800000-?? dx.doi.org/10.1590/S0004-2803. Thus, the aims of this report were to describe the severity of liver fibrosis, comorbidities and complications of HCV; healthrelated quality of life (HRQoL), productivity loss and resource use and costs for the public healthcare system, in a sample of Brazilian Chronic Hepatitis C, genotype 1, patients, as investigated in a multicenter study focused on treatment patterns and disease burden.
METHODS

Study design
This was a cross-sectional multicenter study investigating genotype-1 CHC patients to assess treatment patterns and burden of hepatitis C in the Brazilian public healthcare system between November 2014 and March 2015. The study was conducted in eight specialized centers in CHC treatment located in Southeast (Cities: Belo Horizonte, Botucatu, Rio de Janeiro, São Paulo, and Vitória), South (City: Porto Alegre), and Northeast (City: Recife) Brazilian regions. Patients were submitted to a liver transient elastography (FibroScan) to assess liver fibrosis grade, according to METAVIR score (15) , and to an interview composed by a questionnaire specifically developed for the study and three standardized questionnaires: Euroqol 5-Dimension Questionnaire 3 level version (EQ-5D-3L) (16) , Hepatitis C virus patient-reported outcomes instrument (HCV-PRO) (17) , and HCV-specific Work Productivity and Activity Impairment (WPAI:HepC) (18) .
Subject selection, recruitment and inclusion
Patients were randomly selected to be invited to the study screening process from a list of CHC patients who have attended at least one outpatient visit within the year before the study initiation, as provided by the study sites. Patients ranked by alphabetic ordered were numbered, then a computer generated random number list was used to select patients for screening. The selected patients received a phone call inviting to participate in the study. The patients willing to participate had a study visit scheduled to receive detailed information about the study protocol, signing the informed consent, and initiating the study procedures. Eligible patients were those with diagnosis of CHC genotype 1 as described in medical charts, with at least one outpatient visit during the year previous to study enrollment and aged at least 18 years old. Patients unable to provide informed consent, answer the interview and/or patients who had been enrolled in a clinical trial were excluded.
Data sources and collection methods
The structured interview included questions about sociodemographic and clinical characteristics, and consumption of out-of-pocket resources using a recall period of 12 months prior to inclusion in the study, except for medicines that considered a recall period of three months. Information about medical resources utilization, comorbidities and complications were abstracted from medical charts. Outpatient and hospital resources related to HCV and its complications were collected for a recall period up to 24 months prior to study entry. If the FibroScan test could not be performed at the same day as the interview, a second study visit with a maximum interval of eight weeks was scheduled.
To assess quality-of-life and function and well-being of patients, the following instruments were used, respectively: EQ-5D-3L and HCV-PRO. The EQ-5D-3L is a generic instrument assessing health status through five domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has three levels: no problems, some problems, extreme problems, accordingly, 3 5 =243 combinations of health states are possible. Each of the health states was converted into a utility score between 0 and 1 (representing a scale between death=0 and perfect health=1), using the United Kingdom algorithm which was the standard reference at the time of the study protocol preparation (16, 19) . The questionnaire also includes a Visual Analogue Scale (VAS-EQ) which records respondent's self-rated health, according to endpoints labeled from "Best imaginable health state" to "Worst imaginable health state" (16) . The HCV-PRO is a specific instrument that measures the effects of the disease upon function and well-being. It contains 16 items about how often an experience or limitation was perceived, with levels of response choices ranging from 1=all of the time to 5=none of the time. The total score is the conversion of 16 results into a 0-100 scale. A greater HCV-PRO total score indicates greater levels of function and well-being (17) . The WPAI:HepC measures the effects of hepatitis C on productivity in the workplace and beyond. It is a questionnaire that contains four questions and from these questions it is possible to derivate four domains: percentage of work time missed due to illhealth (absenteeism), percentage of impairment while working due to ill-health (presenteeism), percentage of overall work impairment due to ill-health (absenteeism and presenteeism), and percentage of daily activity impairment due to ill-health. These domains are converted into a 0-100% scale where high percentages represent more impact on productivity (18) . Costs were estimated by multiplying the amount of consumed resources (as self-reported by patients or abstracted from medical charts) for their unit costs. The unit costs sources of tests, outpatient visits, non-drug treatments, and emergency room visits were SIGTAP (System List of Procedures Management, Medicines, Prosthetics and Orthotics, and Specialty Materials of SUS; competency -December, 2015) (20) . The unit cost of hospitalizations/surgical treatments were obtained in SIH (Hospital Information System; competency -2014) of SUS -Unified Health System (21) . The unit costs of drugs were firstly searched in BPS (Health Prices Database) (22) by the lowest and latest purchase price accessible; if the unit cost was not available in BPS, the maximum selling price allowed for Government purchases (PMVG ICMS 0%) in the CMED (Medication Market Regulation Chamber -December 18, 2015) (23) list was used. The reasons for emergency room visits, hospitalizations, and surgical treatments were classified according to International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) (24) . Tests were classified according to Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections (PCDT) (25) , and drugs according to Anatomical Therapeutic Chemical (ATC) code (26) . The unit costs were obtained between December, 2015 and January, 2016 and all data prices were collected in Brazilian Real (BRL) and then converted into American dollar values (USD) using the exchange rate of the date of consultation to the price list (16/Jan/2016), where 1.00 BRL corresponded to 0.2479 USD.
Sample size calculation
This analysis is a part of a larger study designed to estimate the frequency of any specific HCV therapy in the sample (treatment pattern). The original sample size calculation had the purpose to detect a frequency of at least 10% of the triple therapy (pegylated interferon, ribavirin, telaprevir or boceprevir) recommended for HCV patients with METAVIR F3-F4 (that represents 33% of the total population of HCV patients, according to Poynard et al. (27) ). Thus, considering an assumed distribution of triple therapy among all HCV patients of 3% (10% of 33%), a margin of error of 3.0%, and α=0.05, a sample of 318 HCV patients was required. However, 313 patients were included in the study, which provided a 95% confidence interval (CI) with a margin of error of 3.3%. The data presented here are related to secondary outcomes of the aforementioned study.
Statistical analysis
The descriptive analysis was performed through tabulation measures of central tendency (mean) and dispersion (standard deviation-SD) to quantitative variables, and frequency to qualitative variables. The analyses were conducted using Stata (version MP 12 ® ) and R Project (version 3.1.2 © ) to provide a 95% CI and P-value ≤0.05.
Ethical approval
The research was reviewed and approved by Brazilian Independent Ethics Committees of each participating site (Supplementary material 3). The coordinator center approval was obtained in September 12, 2014 (Comitê de Ética em Pesquisa do CRT DST/ Aids, no. 789.165). All procedures were in accordance with the ethical standards of the institutional and national research committee and with the Helsinki declaration and its later amendments or comparable ethical standards.
RESULTS
Sample characterization
Three hundred and eighteen patients were considered potentially eligible; however, five patients did not meet inclusion criteria, resulting in 313 subjects enrolled. TABLE 1 shows the sociodemographic characteristics among included patients. The sample was mainly composed by females (50.8%), Caucasian/white (55.9%) and employed (39.9%). Mean age was 56 (SD=10.4) years old and the predominant educational level was complete high school (29.1%). Only 1.6% and 6.4% of sample presented coinfection HCV/hepatitis B virus (HBV) and HCV/human immunodeficiency virus (HIV), respectively.
Liver fibrosis severity, comorbidities and complications
Cirrhosis was present in 42.8% of HCV patients who underwent FibroScan (FIGURE 1). Cardiovascular (62.6%), metabolic (50.5%), and mental (23.8%) diseases were the most frequent comorbidities, while esophageal varices (54.5%) and portal hypertension (43.6%) were the most frequent complications (TABLE 1) . 
Health-Related Quality of Life (HRQoL)
There were 305 valid responses for EQ-5D-3L. "Pain and discomfort" and "anxiety and depression" were the dimensions with highest HRQoL impairment, in which 55.0% and 47.0% of patients reported to have problems, respectively. "Self-care" was the least affected dimension, with 95.0% of responders reporting absence of problems (FIGURE 2). The mean overall EQ-VAS score was 75.1 (SD 21.4). Patients who reported problems to perform usual activities also presented the lowest score in this dimension according to EQ-VAS -TABLE 2.
Function and well-being
The mean HCV-PRO overall score was 69.1 (SD=24.2). The dimensions presented similar mean scores. The most affected items in patients' perception were those regarding "tiredness" (Q1. mean=3.4; SD=1.3) and "sleep" (Q15. mean=3.4; SD=1.5) -TABLE 3.
Productivity loss
The productivity loss results showed that 79.9% of patients were currently remunerated, 12.4% of patients stopped working due to hepatitis C, and the mean age of work interruption was 49.7 (SD=9.5) years old. HCV caused temporary and permanent income reductions for 11.2% and 5.6% of employed patients, respectively. In addition, 14.4% of patients needed a sick leave in the past 12 months due to hepatitis C, of whom 61.1% received sick leave paid benefits ( • Healthcare system expenses The total direct medical costs with this CHC sample were USD 3,851,691.23 for the past two years, which represented USD 12,305.72 per patient in the 2-year study period (per capita annual costs of USD 6,152.85 -TABLE 7). Drug treatment accounted for 95.9% of the total costs.
Regarding non-medical expenses related to hepatitis C, all resources had low frequency of use among patients, except for the need of transportation in the past 12 months (93.9%). The mean number of trips was 11.3 (SD=14.9) and each travel costed USD 8.83 on average (TABLE 6) .
DISCUSSION
Accurate assessment of liver fibrosis stage has important implications for prognostic, monitoring purposes and is essential for a rational therapeutic decision-making in hepatitis C (28) . FibroScan results showed that most of our sample had cirrhosis. Thus, it is reasonable to consider that most Brazilian HCV patients attending CHC specialized centers have indication to antiviral treatment and require interventions to control known negative cofactors for disease progression. These include life style modifications, as weight loss, alcohol and drug abstinence (28) . There are scarce data regarding the prevalence of liver fibrosis stages determined by FibroScan in Brazil. In fact, our frequencies of severe fibrosis and cirrhosis were much higher than results found by Fernandes et al. Those authors conducted a study in 120 CHC patients and reported the following findings: 54%, 30%, 9%, and 7% for METAVIR stages F0F1, F2, F3, and F4, respectively (29) . Even considering some false positive results of FibroScan or the higher frequency of severe patients in our sample due to the fact that the study sites are specialized centers to where high complexity patients are referred to, it is possible that this higher prevalence of cirrhosis is related to a progressively worse scenario of liver fibrosis among Brazilian patients.
Regarding comorbidities, the frequencies of HCV/HBV and HCV/HIV confections in our sample were lower than those observed in previous Brazilian studies (30, 31) . In a study performed by Carvalho-Filho et al. (30) with 581 CHC patients, 59 (10.2%) individuals had HIV coinfection and 31 (5.3%) had HBV coinfection. Both frequencies were higher than observed in the present study. Another study, carried out by Moia et al. in HCV patients, found a prevalence of HCV/HIV coinfection more than two-fold higher than the one described in this sample (23.9%) (31) . HCV has significant hepatic implication, however it has also been involved in derangements of multiple other organ systems including the muscular, skeletal, nervous, endocrine, cardiovascular, respiratory, and urinary systems (32) . The most common comorbidities in our study were those related to cardiovascular, metabolic and mental diseases, which is consistent with literature data (31, (33) (34) (35) (36) . Previous studies have addressed the role of HCV infection on cardiovascular-related complications (34, 36) , and suggest a strong relationship between HCV infection and the atherogenic process, with high risk of coronary heart disease, carotid atherosclerosis, peripheral artery disease and, ultimately, cardiovascular-related mortality (36) . Regarding metabolic diseases, evidences suggest that HCV interference with glucose and lipid metabolism leads patients to acquire diabetes more frequently (35, 36) . Also, CHC present considerable psychological burden, particularly depression and anxiety (33, 37) , which justifies the presence of mental disorders as a frequent comorbidity.
The EQ-5D-3L index found in the present study was 0.733 [SD 0.28] and is consistent with previously researches conducted in France (0.764 [SD 0.283]) and Canada (0.76 for patients with non-cirrhotic chronic HCV, 0.74 for patients with compensated cirrhosis, and 0.66 for patients with decompensate cirrhosis) (38, 39) . Andrade and collaborators conducted a study using EQ-5D-3L in Brazilian general population. The descriptive analysis showed the following frequencies of patients that presented no problems: mobility (91.23%), self-care (97.59%), usual activities (89.85%), pain/discomfort (57.71%) and anxiety/depression (64.92%) (40) . Thus, except for self-care, HCV patients seem to present higher impairment in HRQoL in all EQ-5D-3L dimensions as compared to the Brazilian general population.
More than 10% of our sample stopped working due to hepatitis C. The mean age of work interruption was 10 years earlier than the regular age of retirement in Brazil for women and 15 years earlier for men. Current literature confirms that CHC patients experience increased work productivity impairment (41, 42) . Besides, our data suggested that presenteeism seems to be more relevant than absenteeism in CHC patients. A similar result was found by DiBonaventura et al. in a European study involving CHC patients (42) . Drugs for CHC are part of the Drug Dispensing Program of the Brazilian Ministry of Health, but are also purchased by State Departments of Health (43) . Therefore, the introduction of new costly technologies implies an economic impact on multiple levels of medical care in the Brazilian healthcare system. In this scenario, real-world data on CHC costs are extremely relevant to support planning and funding of HCV management strategies, for example highlighting disease aspects that are more costly and can be addressed by effective treatment and monitoring, reducing the overall CHC cost for the society.
The HCV per capita annual costs in the present cohort was USD 6,152.85 (BRL 4,819.93). These costs were higher than direct costs of other chronic condition in Brazilian populations, such as diabetes (USD 1,012) (44) , and non-melanoma skin cancer (BRL 1,172) (45) ; but lower than rheumatoid arthritis (BRL 19,860.16) (46) . In addition, the results showed that drug treatment was the costliest component, accounting for 95.9% of total HCV costs; accordingly, a Brazilian study conducted prior to the incorporation of protease inhibitors have shown that drug treatment represented 88.2% of the total costs (47) . We acknowledge some limitations of our study, mainly the possibility of missing data in the patients' medical records. Because it applies to all participants, it is unlikely to result in systematic bias among the different treatments or groups of patients. Secondly, some data were cross-sectionally obtained, which does not allow asserting a temporality between exposure and outcome. In addition, the study patients were from tertiary care centers; consequently, there are limitations regarding the understanding of the disease features in other levels of care. Thirdly, an important caveat is that new DAA prices decreased recently in the country, mainly within the Brazilian public healthcare system, what could lead to lower final costs in future analysis. Another important limitation is the fact that North and Midwest regions were not represented in the sample, which restricts the external validity of the results for the whole country. Finally, this study was conducted between 2014 and 2015 and since then new HCV treatments were made available in SUS, thus the costs exposed here may lack representativeness of currently available therapeutic strategies.
CONCLUSION
To our knowledge, this study presents the most detailed information on HCV Brazilian patients in a real-world setting. The results evidenced that most patients had cirrhosis, with high prevalence of cardiometabolic diseases, esophageal varices, reduced HRQoL mainly in terms of pain/discomfort, and work productivity impairment, especially presenteeism.
Additionally, we demonstrated that HCV imposes an economic burden on Brazilian Healthcare System, and that most of this cost is related to drug treatment. These results have strong implications for clinicians and policy makers, especially with the expanding of the availability of novel therapies in Brazil.
